

Figure S1 ROC curves for the three miRNAs to predict viable GCT. GCT, germ cell tumor.




Figure S2 ROC curves for the three miRNAs to predict teratoma.

miR371a-3p											
	V	N		T	N		VT	N			
V	9	0	9	T	1	0	1	VT	10	0	10
N	7	16	23	N	15	16	31	N	22	16	38
	16	16			16	16			32	16	
miR375-3p											
	V	N		T	N		VT	N			
V	10	3	13	T	14	3	17	VT	24	3	27
N	6	13	19	N	2	13	15	N	8	13	21
	16	16			16	16			32	16	
miR375-5p											
	V	N		T	N		VT	N			
V	12	1	13	T	14	1	15	VT	26	1	27
N	4	15	19	N	2	15	17	N	6	15	21
	16	16			16	16			32	16	
miR371a-3p + miR375-5p											
	V	N		T	N		VT	N			
V	15	1	16	T	15	1	16	VT	30	1	31
N	1	15	16	N	1	15	16	N	2	15	17
	16	16			16	16			32	16	

Figure S3 Contingency table for miR-371a-3p, miR-375-3p, miR371-5p, and miR-371a-3p + miR375-5p to predict viable GCT, Teratoma or both according to optimal cut-points of ROC curves. Cut-off values were: miR-371a-3p >103.4, miR375-3p > 1.0, miR-375-5p >0.76.




Figure S4 ROC curves for the serum tumor markers AFP, hCG and LDH to predict viable GCT and Teratoma. GCT, germ cell tumor; AFP, α -fetoprotein, hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase.